Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Fluphenazine Hydrochloride Tablets, USP in 1mg, 2.5mg, 5mg, and 10mg strengths.

According to IQVIA, the product market had US sales of around USD30m for the 12 months ending January 2023.

The product is a generic version of the brand product, Prolixin. Prolixin is a registered trademark of E.R. Squibb & Sons, Inc.